Accustem Sciences (ACUT) Free Cash Flow (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Free Cash Flow of -$374176.0 for Q1 2026, down 28.95% year-over-year from -$526602.6 in Q1 2025, and down 1773.64% quarter-over-quarter from $22357.0 in Q4 2025.
Accustem Sciences (ACUT) Free Cash Flow (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Free Cash Flow for 5 consecutive years, with -$374176.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 28.95% year-over-year to -$374176.0; the TTM figure through Mar 2026 stood at -$934383.0 (down 30.34% YoY), while the FY2025 annual figure was -$850389.0, down 28.06% from the prior year.
- Free Cash Flow slipped to -$374176.0 in Q1 2026 per ACUT's latest filing, from $22357.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $363781.0 in Q1 2022 and bottomed at -$1.0 million in Q2 2022.
- Historically, Free Cash Flow has averaged -$313019.2 across 5 years, with a median of -$295031.0 in 2023.
- Annual changes were most pronounced in 2023 — Free Cash Flow tumbled 222.63% — and 2025, when it jumped 5300.24%.
- Accustem Sciences' Free Cash Flow stood at -$622261.0 in 2022, then surged by 52.59% to -$295031.0 in 2023, then surged by 100.14% to $414.0 in 2024, then jumped by 5300.24% to $22357.0 in 2025, then tumbled by 1773.64% to -$374176.0 in 2026.
- Business Quant data shows ACUT's Free Cash Flow at -$374176.0 in Q1 2026, $22357.0 in Q4 2025, and -$604131.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | -248,850.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -374,176.00 |
| Mar 31, 2026 | -374,176.00 |
| Dec 31, 2025 | 22,357.00 |
| Dec 31, 2025 | 22,357.00 |
| Sep 30, 2025 | -604,131.00 |
| Sep 30, 2025 | -604,131.00 |
| Jun 30, 2025 | 21,567.00 |
| Jun 30, 2025 | 21,567.00 |
| Mar 31, 2025 | -290,182.00 |
| Mar 31, 2025 | -290,182.00 |
| Dec 31, 2024 | 414.00 |
| Dec 31, 2024 | 414.00 |
| Sep 30, 2024 | -217,947.00 |
| Sep 30, 2024 | -217,947.00 |
| Jun 30, 2024 | -209,182.00 |
| Jun 30, 2024 | -209,182.00 |
| Mar 31, 2024 | -237,351.00 |
| Mar 31, 2024 | -237,351.00 |
| Dec 31, 2023 | -295,031.00 |
| Dec 31, 2023 | -295,031.00 |